(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){ (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o), m=s.getElementsByTagName(o)[0];a.async=1;a.data-privacy-src=g;m.parentNode.insertBefore(a,m) })(window,document,'script','//www.google-analytics.com/analytics.js','ga'); ga('create', 'UA-1666707-3', 'auto'); ga('send', 'pageview');

Regulatory Affairs

    Romania – Notice on Change of Access to Information on Centrally Authorised Medicinal Products

    The NMA hereby informs you on replacement of PDF files in the “Useful Information” section of the main menu, containing the Romanian version of the Summary of Product Characteristics (SPC)

    By |2020-04-01T12:49:09+01:00April 21st, 2009|Regulatory Affairs|0 Comments

      Marketing Authorisation for Medicines via Centralised Procedure in Turkey

      Marketing authorisation could be laso granted for Turkey to comapnies on-going cantalised procedure by EMEA, according to investigation of FarmavitaR+ consultant from Istanbul, Turkey. An application sould be filed in

      By |2020-04-01T12:49:09+01:00February 2nd, 2008|Regulatory Affairs|0 Comments

        Healthcare Brands International Announces the Acquisition of Antula Holdings AB

        Healthcare Brands International (HBI) announces the completion of a major step towards its goal of building a new international Over-the-Counter (OTC) healthcare business with the acquisition of Antula Holdings AB,

        By |2020-04-01T12:49:09+01:00January 8th, 2008|Regulatory Affairs|0 Comments

          Readability (QRD) Testing of Patinet Information Leaflet (PIL)

          Since 2005, marketing authorization holders of medicines are required to have the patient information leafets for their products readability tested. The European Directive 2004/27/EC (a revision of Directive 2001/83/EC) defines

          By |2020-04-01T12:49:14+01:00June 4th, 2007|Regulatory Affairs|0 Comments

            New Legal Framework for Harmonisation of the Data Exclusivity

            The new periods of data exclusivity will only take effect for reference products applying for marketing authorisation after the new law is fully in effect (around November 2005). Therefore, the

            By |2020-04-01T12:49:48+01:00November 29th, 2005|Regulatory Affairs|0 Comments
            Go to Top